Coya Therapeutics Targets ALS and FTD Milestones with $46.8M Cash Runway
Event summary
- Coya Therapeutics enters 2026 with $46.8M cash runway, extending into 2H 2027.
- ALSTARS Phase 2 trial in ALS is actively enrolling with topline data expected in Q1 2027.
- FDA-cleared Phase 2a study in FTD to initiate in Q2 2026 with $5M investment from Alzheimer’s Drug Discovery Foundation.
- COYA 303 Alzheimer’s program advancing via strategic partnerships and non-dilutive funding.
- Collaboration with Dr. Reddy’s Laboratories strengthened, providing non-dilutive milestone payments.
The big picture
Coya Therapeutics is positioning itself as a leader in combination-based Treg modulation therapies for neurodegenerative diseases, a field increasingly recognized for its potential to address complex, multifactorial biology. The company's strategic focus on ALS and FTD—diseases with significant unmet medical needs and combined market opportunities of $2–$4 billion—aligns with broader industry trends toward immuno-neurological convergence. With a strong cash position and key clinical catalysts on the horizon, Coya's ability to execute will determine its long-term valuation and competitive positioning.
What we're watching
- Clinical Validation
- Whether early stabilization signals in ALS and FTD trials will translate into statistically significant outcomes in larger studies.
- Regulatory Strategy
- The pace at which Coya can secure additional regulatory approvals beyond the U.S. and Canada, particularly in high-value markets like Japan.
- Financial Flexibility
- How Coya will balance capital-efficient advancement of COYA 303 while maintaining its cash runway beyond 2027.
Related topics